• Total revenues amount to ??8.4m, mainly thanks to the agreement with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN), which amounts to ??7.8m. The total revenues for 2007 was ??2.8m; • Operating expenses amount to ??7.5m for the first half of 2008. Personnel costs of ??2.1m represent 28% of this total and other operating expenses of ??4.6m represent 61%. Among these other operating expenses: ??1.87m royalties due to Institut Pasteur. Total operating expenses for 2007 amount to ??8.1m; • A healthy balance sheet situation at the end of June 2008, with over ??31m in equity while the net income was of ??1.3m.
Key Points to consider for the first half of 2008
?? Platform o Meganucleases improvement – 1st meganuclease of 3rd generation with high efficacity and specifity; o Meganucleases library extension – ca.13,000 meganucleases (8,000 early 2007).
?? Intellectual Property o Filing of 9 patent applications (2008 objective = 7); o One new patent granted (2008 objective = 2); o European patent n°EP 419 621 (gene targeting process involving homologous recombination) maintained following a hearing before the European Patent Office; o Licensing agreement with a big player – Regeneron Pharmaceuticals Inc. deal.
?? Research & development o Publication of an article in Nucleic Acid Research; o Publication of an article in Methods in Molecular Biology; o Publication of an article in Molecular Therapy; o Publication of an article in Journal of Biological Chemistry.
?? Agreements o Agreement with a biotech company in the field of research tools (2008 objective = 5); o 2 agreements signed with academic partners (2008 objective = 2). ?? Leadership o Hiring of an IP manager and a legal person.
